Keywords: Europe, Counterfeiting, Legislation, EPHA Patient safety

Europe needs new legislation on counterfeiting, says EPHA

Article | 10 December 2009

Contributing to the debate in the European Parliament and Council on the Falsified Medicines Directive from the so-called Pharmaceutical package, the European Public Health Alliance (EPHA) said that patients safety and the access to high- quality medicinal products represent key issues in pharmaceutical policy, but further legislation is required. In this context, the EPHA welcomes the Commission’s legislative initiative aimed at combating counterfeit medicine, and more particularly for the following reasons:

• Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in